Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Accounts Payables (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Accounts Payables over the past 12 years, most recently at $8.7 million for Q4 2025.

  • Quarterly results put Accounts Payables at $8.7 million for Q4 2025, up 305.18% from a year ago — trailing twelve months through Dec 2025 was $8.7 million (up 305.18% YoY), and the annual figure for FY2025 was $8.7 million, up 305.18%.
  • Accounts Payables for Q4 2025 was $8.7 million at Viridian Therapeutics, Inc.\DE, down from $10.1 million in the prior quarter.
  • Over the last five years, Accounts Payables for VRDN hit a ceiling of $14.2 million in Q4 2022 and a floor of $2.1 million in Q4 2024.
  • Median Accounts Payables over the past 5 years was $3.8 million (2023), compared with a mean of $5.4 million.
  • Biggest five-year swings in Accounts Payables: soared 1508.19% in 2021 and later plummeted 84.27% in 2023.
  • Viridian Therapeutics, Inc.\DE's Accounts Payables stood at $2.3 million in 2021, then soared by 511.16% to $14.2 million in 2022, then plummeted by 84.27% to $2.2 million in 2023, then fell by 4.29% to $2.1 million in 2024, then skyrocketed by 305.18% to $8.7 million in 2025.
  • The last three reported values for Accounts Payables were $8.7 million (Q4 2025), $10.1 million (Q3 2025), and $8.5 million (Q2 2025) per Business Quant data.